ASCO 2017: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer

Chicago, IL ( Dr. Matthew Smith and colleagues presented the design for their trial, the ARASENS phase III trial assessing ODM-201 (darolutamide) in men with metastatic hormone-sensitive prostate cancer at the prostate cancer poster session at ASCO 2017. Even with first line therapy (ADT +/- docetaxel or abiraterone, based on the LATITUDE and STAMPEDE studies presented this week), most patients with metastatic hormone-sensitive prostate cancer (mHSPC) progress to castration-resistant prostate cancer (CRPC).

ODM-201 is an investigational oral androgen receptor (AR) antagonist that has a unique chemical structure designed to block the growth of cancer cells through binding to the AR with high affinity and inhibiting the receptor function. In the phase 1 ARAFOR1 and phase 1/2 ARADES2 trials, ODM-201 had antitumor activity and was well tolerated in men with mCRPC. The objective of this trial is to evaluate ODM-201 plus standard ADT + docetaxel in men with metastatic disease.

This international, randomized, double-blind, placebo-controlled, phase III trial is being conducted in 23 countries. Approximately 1,300 men with newly diagnosed metastatic hormone sensitive prostate cancer will be randomized 1:1 to either ODM-201 600 mg twice daily (2×300 mg tablets) orally or placebo, both with ADT + docetaxel (6 cycles after randomization). Patients will be stratified by extent of disease and alkaline phosphatase levels. Inclusion criteria include: (i) histologically confirmed prostate cancer with documented metastases, started ADT ± first-generation anti-androgen therapy ≤12 weeks before randomization, and ECOG performance status 0 or 1. The primary objective is to show superior overall survival (OS) with ODM-201 versus placebo, both with ADT + docetaxel. Secondary end points include (i) time to CRPC, (ii) initiation of subsequent anticancer therapy, (iii) symptomatic skeletal event-free survival (SSE-FS), (iv) time to first SSE, (v) initiation of opioid use, (vi) pain progression, and (vii) worsening of physical symptoms, all measured at 12-week intervals.

This trial is currently open for enrollment in 23 countries worldwide, with the first patient visit occurring in November 2016.
Clinical trial: NCT02799602

Presented By: Matthew R. Smith, MD, PhD, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA

Co-Authors: Fred Saad, Maha Hussain, Cora N. Sternberg, Karim Fizazi, E. David Crawford, Karin Sayuri Yamada, Christian Kappeler, Iris Kuss, Bertrand F. Tombal

Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Twitter: @zklaassen_md

at the 2017 ASCO Annual Meeting - June 2 - 6, 2017 - Chicago, Illinois, USA

1. Massard C, Penttinen HM, Vjaters E, et al. Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naïve Metastatic Castration-resistant prostate cancer: An Open-Label Phase 1 study. Eur Urol 2016 May;69(5):834-840. 

2. Fizazi K, Massard C, Bono P, et al. Activity and safetly of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomized phase 2 dose expansion trial. Lancet Oncol 2014 Aug;15(9):975-985.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.